AACR 2018: “Universal” CAR T-Cell Product Could Make Treatment More Accessible – R & D Magazine
R & D Magazine |
AACR 2018: “Universal” CAR T-Cell Product Could Make Treatment More Accessible
R & D Magazine FT819, an off-the-shelf, T-cell receptor (TCR)-less CD19 CAR T-cell product—created from cells of a healthy donor rather than the patient themselves—could potentially make CAR–T cell treatment more accessible to cancer patients than conventional … The Newest, Undiscovered CAR–T Play with a Rock-Star Partner Portfolio & Significant Near-Term Upside Potential ACEA Biosciences Hosted Cancer and Immunotherapy Symposium for Leading Scientists in T Cell Therapy Dendritic Cell and CAR–T Therapies Market to make Great Impact in near Future by 2025 |
